SOHM announces appointment of G. Michael Bennett to chair Of Advisory Board Team

CORONA, CA--(Marketwired - December 04, 2014) - SOHM, Inc. (OTC PINK: SHMN), a manufacturer of generic Pharmaceutical, Nutraceutical and Cosmeceutical drug products, today announces the appointment and joining of its Advisory Board Member Chair.

Shailesh Shah, President and CEO of SOHM, Inc., is happy to announce today that Mr. G Michael Bennett has joined SOHM as the Chair of the Advisory Board, whose mission is to develop the international presence of SOHM and to facilitate the firm's growth and breath.

Mr. Bennett has an extensive background of working as Chief Financial Officer, Controller, CPA, professor, CEO, Chairman/Advisor for several Advisory Boards, and as NED for several Boards of Directors.

His education includes both a BA and an MBA from Michigan State University. Mr. Bennett has taught at the University of Hawaii, Chaminade University at Honolulu, Chapman University and California State University at Fullerton.

Further Mr. Shah states that Mr. Bennett is current on the rules and regulations of main boards including NASDAQ, Amex/NYSE EuroNext and HKEx. (GEM and the Main Board), as well as being current on pronouncements and requirements of the SEC, FINRA, US -GAAP, PRC -GAAP, SOX, Dodd-Frank, FCPA and related. Moreover he is experienced with China's rules and regulations and trends.

Along with an extensive working knowledge of financial reporting, accounting systems, forecasting/budgeting, corporate governance, internal controls and cash flow requirements, Mr. Bennett has developed extensive relations with many PE firms, investors of a variety of sizes and focus, CPAs, attorneys, underwriters, regulators and others key to SOHM's success internationally in the near future.

SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Besides generic drugs, SOHM also has manufacturing facilities for food supplements and cosmetics. The Company has global headquarters located in California, U.S., with manufacturing facilities in India. SOHM exports generic pharmaceuticals worldwide, placing a heavy focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. For more information visit the company's website at:

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results. 

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.